Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

Simply Wall St.09-28

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470475630?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2024-09-28 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470475630","market":"sg","top_or_hot":-1,"title":"Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth","media":"Simply Wall St.","content":"<div>\n<p>We can readily understand why investors are attracted to unprofitable companies.   For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgls/regulus-therapeutics/news/companies-like-regulus-therapeutics-nasdaqrgls-are-in-a-posi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompanies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-28 20:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgls/regulus-therapeutics/news/companies-like-regulus-therapeutics-nasdaqrgls-are-in-a-posi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We can readily understand why investors are attracted to unprofitable companies.   For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgls/regulus-therapeutics/news/companies-like-regulus-therapeutics-nasdaqrgls-are-in-a-posi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgls/regulus-therapeutics/news/companies-like-regulus-therapeutics-nasdaqrgls-are-in-a-posi","article_id":"2470475630","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470475630","pubTimestamp":1727527653,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","RGLS":"Regulus Therapeutics Inc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","QID":"纳指两倍做空ETF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","BK4585":"ETF&股票定投概念","BK4139":"生物科技",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Regulus Therapeutics（纳斯达克股票代码：RGLS）等公司有能力投资增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGLS":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"We can readily understand why investors are attracted to unprofitable companies.   For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune.   But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.  So, the natural question for Regulus Therapeutics (NASDAQ:RGLS) shareholders is whether they should be concerned by its rate of cash burn.   In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth.  First, we'll determine its cash runway by comparing its cash burn with its cash reserves.  View our latest analysis for Regulus Therapeutics  When Might Regulus Therapeutics Run Out Of Money?  You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash.   In June 2024, Regulus Therapeutics had US$94m in cash, and was debt-free.   In the last year, its cash burn was US$34m.   That means it had a cash runway of about 2.8 years as of June 2024.     Arguably, that's a prudent and sensible length of runway to have.    The image below shows how its cash balance has been changing over the last few years. NasdaqCM:RGLS Debt to Equity History September 28th 2024  How Is Regulus Therapeutics' Cash Burn Changing Over Time?  Regulus Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business.  So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time.     With the cash burn rate up 23% in the last year, it seems that the company is ratcheting up investment in the business over time.  However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase.    Clearly, however, the crucial factor is whether the company will grow its business going forward.  For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.   How Hard Would It Be For Regulus Therapeutics To Raise More Cash For Growth?  Given its cash burn trajectory, Regulus Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway.    Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business.  One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth.  By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).  Regulus Therapeutics has a market capitalisation of US$103m and burnt through US$34m last year, which is 33% of the company's market value.    That's not insignificant, and if the company had to sell enough shares to fund another year's growth at the current share price, you'd likely witness fairly costly dilution.   How Risky Is Regulus Therapeutics' Cash Burn Situation?  Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Regulus Therapeutics' cash runway was relatively promising.     Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn.      On another note, Regulus Therapeutics has 3 warning signs (and 2 which are a bit unpleasant) we think you should know about.   If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow. New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470475630"}